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ABSTRACT
Glioblastoma recurrence after aggressive therapy typically occurs within six
months, and patients inevitably succumb to their disease. Tumor recurrence is driven
by a subpopulation of cancer stem cells in glioblastoma (glioblastoma stem-like cells,
GSCs), which exhibit resistance to cytotoxic therapies, compared to their non-stem-cell
counterparts. Here, we show that the Cox-2 and Wnt signaling pathways are aberrantly
activated in GSCs and interact to maintain the cancer stem cell identity. Cox-2 stimulates
GSC self-renewal and proliferation through prostaglandin E2 (PGE2), which in turn
activates the Wnt signaling pathway. Wnt signaling underlies PGE2-induced GSC selfrenewal and independently directs GSC self-renewal and proliferation. Inhibition of
PGE2 enhances the effect of temozolomide on GSCs, but affords only a modest survival
advantage in a xenograft model in the setting of COX-independent Wnt activation. Our
findings uncover an aberrant positive feedback interaction between the Cox-2/PGE2
and Wnt pathways that mediates the stem-like state in glioblastoma.

Highlights

after surgery, radiation and chemotherapy, typically
occurs within six months, and patients inevitably
succumb to disease progression at just over one year [1].
Emerging recognition of the cellular heterogeneity within
glioblastoma has focused attention on a subpopulation
of cancer stem cells (CSCs) in glioblastoma, called
brain tumor-initiating cells or glioblastoma stem-like
cells (GSCs) [2], that are thought to contribute to tumor
recurrence following therapy. Compared to their nonstem-cell counterparts (differentiated glioma cells,
DGCs), GSCs exhibit resistance to chemotherapy- and
radiation-induced cell death [3–5], often through cooption of signaling pathways relevant to normal stem cell
physiology [6–9]. Conceivably, these pathways could be
therapeutic targets to disable CSC-mediated treatment
resistance.

• Cox-2 and Wnt signaling pathways are aberrantly
activated in GSCs
• Cox-2 stimulates GSC self-renewal and proliferation
through prostaglandin E2 and activated Wnt
• Wnt signaling underlies PGE2-induced GSC selfrenewal and independently directs GSC self-renewal
and proliferation
• PGE2 inhibition enhances temozolomide cytotoxicity
but fails to prevent tumor progression because of COXindependent Wnt activation

INTRODUCTION
Despite advances in therapy, outcomes for patients
with glioblastoma remain dismal. Disease recurrence
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RESULTS

Cyclooxygenase-2 (Cox-2) is an inducible enzyme
that plays a key role in the production of the bioactive
lipid, prostaglandin E2 (PGE2). Cox-2 has been shown
to play an important role in several human cancers,
including glioblastoma. In prostate and colon cancer,
elevated Cox-2 expression has been associated with
increased angiogenesis, tumor invasion and promotion
of tumor cell resistance to apoptosis [10–13]. Elevated
Cox-2 levels have also been found to correlate with
earlier recurrence and shorter survival in patients with
gliomas [14].
In addition to its roles in angiogenesis, tumor
invasion, and tumor cell survival, the Cox-2/PGE2
pathway may play a role in maintaining the cancer stemlike cell population and preserve self-renewal capacity in
GBM. Cox-2 has been found to regulate glioma stem-like
cell (GSC) proliferation [15, 16], and Cox-2-derived PGE2
promotes self-renewal and imparts radiation resistance in
an RCAS-Tva GBM mouse model [17] and in multiple
glioblastoma cell lines [18].
In the hematopoietic stem cell niche, Cox-2
regulates vertebrate HSC induction and engraftment
directly through production of PGE2 [19], and indirectly
through stabilization of β-catenin protein and activation
of the Wnt pathway [20]. In the adult mouse brain,
activation of the canonical Wnt signaling (Wnt/β-catenin
pathway) is not seen under resting state conditions,
but is expressed when progenitor cells are dividing
symmetrically, that is, during subependymal zone
regeneration, following stroke, or during neurosphere
formation [21]. Aberrant activation of Wnt signaling in
the subventricular zone results in symmetric expansion
of the NSC pool. Interestingly, the activating effect of
Wnt on embryonic stem cell self-renewal has been found
to depend on its induction of Egr1 [22], which has also
been implicated as a downstream target of the Cox-2
pathway [23].
Cancer stem cell systems have been described
as hierarchies in which the normal mechanisms by
which stem cells systems are maintained have been
dysregulated to allow uninhibited cell expansion and
growth [24]. Here, we show that Cox-2 is constitutively
activated in human GSCs, but not in normal human
neural stem cells (NSCs). Cox-2 signaling and
production of PGE2 results in increased GSC
proliferation and self-renewal in both GSCs and NSCs
in vitro, while inhibition of Cox-2 in GSCs induces
cell differentiation and loss of the cancer stem-like
cell phenotype. PGE2 further promotes the GSC state
through its activation of the Wnt/β-catenin pathway,
which mediates PGE2-induced GSC self-renewal
through its canonical pathway. Our findings uncover
an aberrant interaction between the Cox-2/PGE2 and
Wnt pathways that mediates the stem-like state in
glioblastoma.

www.impactjournals.com/oncotarget

Cox-2 is expressed in human glioblastoma
To examine Cox-2 expression in human glioma,
we first performed immunohistochemistry for Cox-2 in
low- and high-grade glioma surgical specimens. These
studies showed Cox-2 expression in gliomas and in glioma
cells within infiltrated brain (Figure 1A). We found no
expression of Cox-2 within the normal brain hemisphere
or within the neurogenic regions of the adult mouse
subventricular zone or subgranular zone (Supplementary
Figure 1). Examination of glioma expression data from
The Cancer Genome Atlas (TCGA) demonstrated that
Cox-2 expression increases with increasing tumor grade
(Figure 1B) and is enriched in the mesenchymal subgroup
(Figure 1C).

Cox-2 is enriched in GSCs and promotes GSC
proliferation through PGE2
As Cox-2 has been implicated as a mediator of
the cancer stem cell phenotype in mouse glioblastoma,
we sought to determine if it has an analogous role in
the human disease. We generated low-passage RFPexpressing patient-derived GSC lines that express neural
stem cell markers (Figure 2A), form self-renewing
neurospheres (Figure 2B), and give rise to infiltrative
brain tumors following orthotopic transplantation in
immunocompromised mice [25] (Figure 2C). Western blot
analysis utilizing GSCs and NSCs in culture confirmed
that Cox-2 is basally expressed in GSCs, but not in
human fetal NSCs (Figure 2D). Analogous to gross tumor
expression data from TCGA, Cox-2 expression is higher
in GSCs generated from high-grade gliomas than in GSCs
generated from low-grade gliomas in culture. We found
no evidence of basal Cox-1 expression in either GSCs or
NSCs (Figure 2E). Prostaglandin E2 (PGE2) production
was limited to glioma cells with high levels of basal Cox-2
expression (Figure 2F).
As has been found in glioma cell lines and a
mouse glioblastoma model, we postulated that Cox2 activation could have a pro-proliferative effect on
human GSCs through production of PGE2. Inhibition
of PGE2 production in GSCs using the nonselective
cyclooxeganse inhibitor, indomethacin, the specific Cox2 inhibitor, celecoxib, or siRNA against COX-2, resulted
in a significant decrease in cell proliferation, compared to
treatment with vehicle or control siRNA (Figure 3A-3C).
In contrast, treatment with the synthetic PGE2 analog,
iloprost, resulted in enhanced proliferation in both GSCs
and NSCs (Figure 3D). Finally, inoculation of a heterotopic
patient-derived glioblastoma xenograft (PDX) with
indomethacin resulted in slowed tumor growth, compared
to tumors injected with a vehicle control (Figure 3E).
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Cox-2 regulates stem-ness in GSCs

and Wnt pathways in the regulation of HSC proliferation
[20]. Wnt pathway activation has also been postulated to
regulate symmetric cell division in normal NSCs [27, 28].
To determine if Wnt signaling regulates cell cycle entry
in GSCs, we first looked for evidence of Wnt pathway
activation in GSCs by immunoblotting for β-catenin
accumulation in multiple GSC lines. We found β-catenin
accumulation in multiple GSCs and glioma cell lines, but
not in human fetal NSCs (Figure 5A).
We then sought to determine if PGE2 regulates the
Wnt pathway in glioblastoma. Treatment of GSCs with
iloprost resulted in an increase in β-catenin activation,
as demonstrated by accumulation of phosphorylated
β-catenin (Figure 5B) [29–31]. Conversely, PGE2
inhibition with indomethacin, celecoxib, or siRNA
against COX-2, resulted in a significant decrease in
phosphorylated β-catenin in GSCs (Figure 5C). To
determine if PGE2 is relevant to canonical Wnt signaling,
we then examined the effect of Cox-2 pathway modulation
on the expression of LEF1 and TCF7, two Wnt pathway
co-activators that mediate β-catenin binding to the genome
[32], and the Wnt targets, AXIN2 and CCND1 [33, 34].
PGE2 induction with iloprost resulted in an increase in
AXIN2, LEF1, TCF7, and CCND1 expression, while
PGE2 inhibition with indomethacin, celecoxib, or siRNA

We then sought to determine if Cox-2 signaling
regulates the CSC identity in glioblastoma. Treatment of
GSCs with indomethacin, celecoxib, or siRNA against Cox2, resulted in a significant decrease in expression of the GSC
marker Sox2, and an associated increase in expression of
the differentiation markers, GFAP and β-tubulin (Figure
4A). Conversely, treatment of GSCs with iloprost resulted
in a significant increase in expression of the GSC marker
Sox2, and an associated decrease in expression of the
differentiation markers, GFAP and β-tubulin, in multiple
GSCs and the U87 glioblastoma cell line (Figure 4B).
Cox-2 expression in glioma cells also decreased following
forced differentiation (Figure 4C). Further, Cox-2 inhibition
was accompanied by a decrease in GSC self-renewal, as
approximated by sphere formation [26] (Figure 4D-4F),
while treatment with the PGE2 analog, iloprost, promoted
GSC sphere formation (Figure 4G). These findings suggest
that Cox-2 signaling is necessary to maintain the cancer
stem-like cell phenotype in glioblastoma.

PGE2 activates the Wnt pathway in GSCs
Investigation of the hematopoietic stem cell system
has demonstrated a close association between the PGE2

Figure 1: Cox-2 is expressed in human glioblastoma. (A) Immunohistochemistry for Cox-2 shows abundant expression in highgrade glioma (BT2011064, BT2012104), with lower expression in low-grade glioma (BT2013034) and infiltrated brain. (B, C) Analysis of
expression data from The Cancer Genome Atlas (TCGA). Cox-2 mRNA levels increase with increasing glioma grade and is enriched in the
mesenchymal subgroup. Data are represented as mean ± SEM.
www.impactjournals.com/oncotarget
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Figure 2: Cox-2 is enriched in GSCs and results in production of PGE2. (A) GSC lines were subjected to
immunofluorescence with antibodies against Sox2 (red) or nestin (green), and Hoechst nuclear stain (blue). (B) RFPexpressing GSCs were grown as gliomaspheres and (C) injected into the right putamen of NOD-SCID mice. Animals were
sacrificed after 2 months. Sectioned brains were subjected to Brightfield microscopy and immunofluorescent microscopy
for RFP. (D) Relative quantification of COX-2 protein levels as determined by Western blot analysis of lysates from HGGderived GSCs (GliNS1, 2012087, G179, 2014035), LGG-derived GSCs (2015098, 2014036, 2015089, 2014057), and human
fetal NSCs (hfNS1, hfNS2). (E) Cox-1 and Cox-2 protein expression in GSCs (GliNS1, 2012087, G179, 2014035, 2015098,
2014036, 2015089, 2014057) compared to hfNSCs (hfNS1, hfNS2). (F) PGE2 production in GSCs with high (GliNS1,
2012087) or low (2015089, 2014057) basal Cox-2 expression. Data are represented as mean ± SEM.
www.impactjournals.com/oncotarget
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against COX-2, resulted in a significant decrease in
AXIN2, LEF1, TCF7, and CCND1 expression (Figure
5D). Our findings indicate the Cox-2 promotes activation
of the Wnt signaling pathway in GSCs.

Wnt inhibition with pyrvinium abrogated the inductive
effect of iloprost on GSC self-renewal, as approximated by
sphere formation (Figure 6E), but not GSC proliferation
(data not shown). As would be expected by these findings,
analysis of GSCs and DGCs from the Bernstein dataset
shows an enrichment of TCF7 and LEF1 target genes, as
identified by Gene Ontology analysis, in GSCs compared
to DGCs [37] (Figure 6F). Together, these data indicate
that Wnt pathway activation promotes proliferation and
self-renewal in GSCs, and that Wnt signaling may mediate
the inductive effect of PGE2 on self-renewal [38].

Wnt pathway activation mediates self-renewal in
GSCs
To determine the role of Wnt/β-catenin pathway in
GSCs, we studied the effect of Wnt pathway activation
and inhibition on GSCs in vitro. Wnt pathway activation
with lithium chloride, which stabilizes endogenous
β-catenin through inhibition of GSK3β [35], resulted in a
significant increase in both GSC proliferation (Figure 6A)
and self-renewal, as approximated by sphere formation
(Figure 6B) in vitro. Conversely, treatment with the casein
kinase-1α potentiator pyrvinium, which has been shown
to inhibit the Wnt pathway inhibition by potentiating
Axin-mediated degredation of β-catenin [36], resulted in
a significant decrease in both GSC proliferation (Figure
6C) and sphere formation (Figure 6D). Wnt signaling had
no apparent effect on GSC survival, as determined by
expression of caspase-3 (data not shown). Interestingly,

COX-2 inhibition enhances the effect of
temozolomide in glioblastoma
CSCs have been postulated to drive tumor
recurrence following disease treatment through their
preferential resistance to cytotoxic injury and cell death
[3, 4, 39]. To determine if this hypothesis could be
relevant to glioblastoma, we examined the effect of COX2 signaling on cell survival following chemotoxic stress
caused by exposure to the alkylating agent, temozolomide.
Temozolomide is used as a first-line chemotherapeutic

Figure 3: Inhibition of PGE2 production results in decreased GSC proliferation. (A) Cox inhibition with indomethacin (IM)

results in decreased proliferation in GSCs, as determined by absolute cell count. (B, C) Selective Cox-2 inhbition with celecoxib (50 μM)
or siRNA against COX-2 (siRNA-COX2) results in decreased proliferation in GSCs, as determined by absolute cell count. (D) Treatment
of GSCs with the synthetic PGE2 analog, iloprost (IL, 100 μM), promotes cell proliferation in GSCs (GliNS1, 2012087, G179) and NSCs
(hfNSC1, hfNSC2), as determined by absolute cell count. * p <0.005, **p < 0.01. (E) Intratumoral inoculation with indomethacin (5021,
5022, 5025, 5027) impairs tumor growth in a heterotopic GBM xenograft model, compared to inoculation with control (5023, 5024, 5026,
5028). Data are represented as mean ± SEM.
www.impactjournals.com/oncotarget
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agent in patients with glioblastoma, and its use has been
shown to increase overall and progression-free survival
(Stupp et al). GSCs treated with iloprost and temozolomide
demonstrated lower levels of cell death and DNA damage,
as determined by absolute cell count and staining for
phosphorylated histone H2AX (γH2AX), compared to
GSCs treated with temozolomide alone (Figure 7A and
7B). Conversely, concurrent COX-2 inhibition with
indomethacin, celecoxib, or siRNA against COX-2,
increased the cytotoxic effect of temozolomide on GSCs,
as demonstrated by absolute cell counts (Figure 7C).
As would be predicted by these findings, indomethacin

potentiated the effect of temozolomide chemotherapy on
overall survival in a mouse orthotopic xenograft model
(Figure 7D), though disappointingly the survival benefit
was limited and non-sustained. Interestingly, we found
evidence of sustained nuclear β-catenin staining within
surviving glioma cells in xenograft-harboring mice
treated with temozolomide and indomethacin compared
to xenograft-harboring mice treated with temozolomide
alone (Figure 7E), contrary to results that would be
expected from our in vitro findings that COX inhibition
results in decreased Wnt activation in glioma cells. The in
situ findings support the presence of a COX-independent

Figure 4: Cox-2 regulates stem-ness in GSCs. (A) Coxinhibition with indomethacin or Cox-2 inhibition with celecoxib (50 μM) or

siRNA-COX2 in GliNS1 GSCs results in decreased expression of the stem-ness marker, Sox2, and increased expression of the differentiation
markers, GFAP and β-tubulin. (B) Treatment with iloprost (100 μM) results in increased expression of the stem-ness marker, Sox2, and
decreased expression of the differentiation markers, GFAP and β-tubulin, in GSCs (2012016, 2012018, 201431, 2014046, 2014057), and
the U87 glioblastoma cell line. * p <0.01, **p < 0.05. (C) Cox-2 expression in the GSC line GliNS1 following forced GSC differentiation
by withdrawal of growth factors and treatment with serum. (D-F) Coxinhibition with indomethacin or Cox-2 inhibition with celecoxib
(50 μM) or siRNA-COX2 results in decreased self-renewal in GliNS1 GSCs, as measured by the sphere formation assay. (G) Treatment
of GliNS1 GSCs with iloprost (100 μM) results in increased GSC self-renewal, as measured by sphere formation. Data are represented as
mean ± SEM.
www.impactjournals.com/oncotarget
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mechanism for activation of the Wnt pathway in glioma
cells located within the brain microenvironment, and
suggest a mechanism underlying the limited survival
benefit conferred by concomitant COX inhibition therapy.

Knockout of the COX-2 gene led to a marked reduction in
the size and number of polyps in APCD716 mice, as did
selective pharmacologic Cox-2 inhibition [40]. Exogenous
Cox-2 expression sensitizes mouse skin to carcinogenesis
[41], while COX-1 or -2 knockout inhibits skin papilloma
formation [42]. Several epidemiologic studies have since
shown an inverse correlation between the incidence of
colon cancer and the use of nonsteroidal anti-inflammatory
drugs (NSAIDs), which inhibit prostaglandin synthesis
[43–45]. Similarly, WNT1 overexpression induced by a
proviral insertion at the Wnt1 locus induces spontaneous
mammary hyperplasia and tumours in mice [46, 47],
and Wnt1 transgenic mice similarly develop mammary
tumours, suggesting a causative role for WNT1 in breast
cancer tumorigenesis [48]. Activating Wnt mutations
have also been found in colorectal cancer, Wilms tumors,
hepatocellular carcinoma (HCC) [49], medulloblastoma
[50] and ovarian cancer [51].
Zon and colleagues have previously identified an
interaction between the Wnt and prostaglandin signaling
networks in murine stem and progenitor populations in the
hematopoietic system [20]. In the hematopoietic system,
PGE2 modified the Wnt signaling cascade at the level of
β-catenin degradation through a cAMP/PKA-mediated

DISCUSSION
In this study, we identify a cooperative role for
Cox-2 and Wnt/β-catenin as mediators of the CSC
phenotype in glioblastoma. Cox-2 is enriched in GSCs
and promotes GSC proliferation and self-renewal through
PGE2. Inhibition of Cox-2 directs glioma cells toward
a differentiated phenotype and inhibits proliferation and
self-renewal. As in the hematopoietic stem cell system,
PGE2 activates the Wnt pathway in glioblastoma, resulting
in increased levels of β-catenin and phosphorylated
β-catenin. Finally, inhibition of the Wnt pathway abrogates
the stimulatory effect of PGE2 on GSC self-renewal,
suggesting that the modulatory effect of Cox-2 on GSC
self-renewal is Wnt-dependent.
The Cox-2/PGE2 and Wnt/β-catenin pathways have
been studied intensively as oncogenic drivers and are
viewed as promising targets in several human cancers.

Figure 5: The Wnt pathway is activated in GSCs and enhanced by COX-2 signaling. (A) Western blot analysis for β-catenin in

untreated HGG-derived GSCs (GliNS1, 2012087, G179, 2015098), U87 MG, and human fetal neural stem cells (hfNS1). (B) Treatment of
GliNS1 GSCs with iloprost (100 μM) results in increased expression of activated β-catenin (Ser675). (C) Coxinhibition with indomethacin
or Cox-2 inhibition with celecoxib (50 μM) or siRNA-COX2 results in decreased expression of activated β-catenin in GliNS1 GSCs. (D)
qRT-PCR for Wnt pathway targets AXIN2 and CCND1 and co-activators LEF1 and TCF7, following treatment of GliNS1 GSCs with the
PGE2 agonist iloprost (100 μM) or Coxinhibition with indomethacin or Cox-2 inhibition with celecoxib (50 μM) or siRNA-COX2. * p <
0.001. Data are represented as mean ± SEM.
www.impactjournals.com/oncotarget
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phosphorylation event that stabilizes β-catenin. Similarly,
Ferrari and colleagues has found that Wnt/β-catenin
signaling enhances the transcription of COX2 in gastric
cancer cells by binding to a TCF/LEF-response element
in the COX2 promoter [52].
Our results demonstrate a role for Cox-2/PGE2
signaling as a regulator of the GSC identity, and reinforce

a therapeutic rationale for but possible limitation of Cox-2
inhibitors in glioblastoma. Chemical or genetic inhibition
of PGE2 production results in differentiation of GSCs and
inhibition of GSC proliferation and self-renewal. PGE2
production also results in activation of the Wnt/β-catenin
pathway, which in turn stimulates GSC proliferation
and self-renewal. Interestingly, Wnt inhibition abrogates

Figure 6: Wnt pathway activation mediates self-renewal in GSCs. (A, B) Wnt activation in GSCs through treatment with the

GSK3b-inhibitor lithium chloride (10 mM) promotes GliNS1 GSC proliferation and self-renewal, as determined by BrdU incorporation
and sphere formation. (C, D) Wnt pathway inhibition with the casein kinase-1α potentiator pyrvinium (100 nM) results in decreased
GliNS1 GSC proliferation and self-renewal, as determined by BrdU incorporation and sphere formation. (E) Wnt pathway inhibition with
pyrvinium (10 nM) counteracts the stimulatory effect of PGE2 induction with iloprost (100 μM) on sphere formation in GliNS1 GSCs. (F)
Wnt target genes are enriched in GSCs compared to differentiated glioma cells (DGCs) in the Bernstein dataset. Data are represented as
mean ± SEM.
www.impactjournals.com/oncotarget
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the positive effect of PGE2 induction on GSC sphere
formation, suggesting the stimulatory effect of COX-2 on
GSC self-renewal is mediated through the Wnt pathway.
This finding is intriguing, as Wnt signaling has also been
found to direct symmetric cell division in adult mouse
NSCs [21], and has been found to be a critical target of
PGE2 during HSC specification and regeneration [20].
Our findings also suggest that cell-extrinsic, PGE2independent activation of the Wnt pathway could mitigate
a therapeutic benefit of Cox-2 inhibition in glioblastoma. It
is tempting to speculate that the lack of significant clinical
efficacy of COX-2 inhibition in our animal data and in
the clinical experience with patients with glioblastoma
may be explained by our finding in situ of increased Wnt
activation in the setting of IM therapy. It may very well
be that concurrent use of Wnt inhibitors will ameliorate
this deficit.
The Wnt signaling pathway has recently been
described to be constitutively activated in a subgroup
of glioblastomas, and it is possible that the kinetics of
mitosis in these tumors favors self-renewal rather than
proliferation as the vector for tumor expansion [53, 54].
It is intriguing to speculate that Wnt signaling could play
a role in GBM treatment resistance and tumor recurrence

[55, 56], and in this context, underlie resistance to Cox
inhibition therapy. Our data also reinforce prior findings
that proliferation and self-renewal are molecularly distinct
processes in glioblastoma, and prompt further study
to understand the role of self-renewal in glioblastoma
development, progression and recurrence.

Experimental procedures
The experimental work included in this manuscript
was performed at the University of Toronto, Toronto,
Ontario, and Washington University, St. Louis, Missouri.
All experiments were performed in accordance with
the relevant guidelines and regulations of these two
institutions.

Immunohistochemistry in human glioblastoma
specimens
Human glioblastoma specimens and clinical data
were obtained from the St. Michael Hospital Brain Tumour
Biobank and Brain Tumour Research Centre, Hospital for
Sick Children, following approval by the Institutional
Research Ethics Boards of both institutions. All samples
were de-identified before analysis. Tissue samples were

Figure 7: COX-2 inhibition enhances the cytotoxic effect of temozolomide in glioblastoma. (A) Concurrent treatment of

GSCs with iloprost (100 μM) protects GSCs (GliNS1, 2012087) from the cytotoxic effect of temozolomide (50 μM), as determined by
absolute cell count. (B) γH2AX foci in GliNS1 GSCs treated with temozolomide (50 μM) with or without iloprost (100 μM). (C) Concurrent
Cox inhibition with indomethacin (IM) or Cox-2 inhibition with celecoxib (50 μM) or siRNA against COX-2, potentiates the cytotoxic
effect of temozolomide (50 μM) on GliNS1 GSCs. (D) Kaplan-Meier curve showing survival in a mouse glioblastoma orthotopic xeongraft.
Treatment with the Cox inhibitor indomethacin had no direct effect on overall survival, but enhanced the survival benefit proffered by
treatment with temozolomide. (E) No statistically significant difference (p=0.46) in the relative percentage of nuclear β-catenin-positive
cells among surviving RFP-positive glioma cells in xenograft-harboring mice treated with temozolomide and indomethacin (n=4) compared
to xenograft-harboring mice treated with temozolomide alone (n=4). Data are represented as mean ± SEM.
www.impactjournals.com/oncotarget
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Xenotransplantation

preserved in 10% formalin, dehydrated and embedded in
paraffin. Five μm sections were immunostained for COX2 (Abcam 1:1000), with antigen retrieval using pressure
cooking in 10uM citrate buffer at pH6.0, secondary
HRP anti-Rabbit IgG (Vector lab 1:250), and detection
using DAB Substrate kit (Vector lab). Nuclei were
counterstained with DAPI (0.002 mg/ml Sigma) for 10
minutes, washed and mounted with Vectashield mounting
medium (Vector Laboratories, Inc.). Images were acquired
with a Quorum Spinning Disk Confocal Microscope
(Olympus) running Volocity software (Perkin Elmer).

Animal studies were performed in accordance with
the Toronto Centre for Phenogenomics (TCP) institutional
animal protocols and approved by the Animal Studies
Committee of the University of Toronto. For heterotopic
(flank) model studies, 50,000 cells were injected in the
mouse flank of approximately 6-week-old NOD-SCID
mice. Drug administration in the flank xenograft model
was performed through direct intratumoral injection
using a volume of 200 uL per injection of either normal
saline (0.9%) or 1.5 mM indomethacin. A total of five
intratumoral injections were given every other day. The
mice were checked daily and sacrificed 24 hours after the
last injection. For orthotopic (intracranial) model studies,
25,000 cells were injected stereotactically into the right
putamen of approximately 6-week-old NOD-SCID mice.
The coordinates used were: 1 mm rostral to bregma, 2 mm
lateral, and 2.5 mm deep.

Analysis of COX2 expression in glioblastoma
from TCGA
TCGA GBM RNAseq data was accessed using
TCGA-Assembler [57]. RSEM normalized reads for
COX2 were extracted and plotted using custom scripts in
R. Differential expression between molecular subgroups
were assessed using a Welch’s two-sample t-test.

Western blotting and protein quantification

Cell culture
The generation of adherent human GSC cultures
has been described previously [25]. Informed consent
was obtained from patients for use of human tissue
and cells, and all human tissue-related protocols used
in this study were approved by the Review Ethics
Board (University of Toronto). In brief, tumor samples
obtained directly from surgery were dissociated by
mincing and incubation in Accutase (Sigma-Aldrich) for
20–60 min at 37C. Cell suspensions were passed through
a 70-mm cell strainer (Falcon) and plated using Ndiff
RHB-A media (Stem Cell Sciences) with EGF and FGF2 (PeproTech) (hereafter called GSC media) each at 20
ng/ml, on polyornithine- and laminin- (Sigma- Aldrich)
coated Primaria dishes/flasks (BD Biosciences). Media
were replaced with half fresh GSC media every 2–3
days. Cells were routinely used between passages 5 and
20. U87 cells were cultured in DMEM with 10% fetal
bovine serum (FBS) and penicillin/streptomycin (Life
Technologies). All cell lines were incubated at 37°C
with 5% CO2.

Cells were washed with cold PBS and lysed. Cell
lysates were shaken at 4°C for 10 min and centrifuged
at 14,000 × g for 10 min. Protein concentrations in the
supernatants were quantified using the BCA protein
assay. Fifteen micrograms of protein were separated
on 10% acrylamide/bisacrylamide gels and transferred
to PVDF membranes. PVDF membranes and blocked
with 5% (w/v) skim milk in PBS/0.1% Tween-20 for 1
h at room temperature. Membranes were shaken with
primary antibodies at 4°C overnight, then washed and
incubated with secondary antibodies (Cell Signaling) for
1 hr at room temperature. ECL (Bio-Rad) was used for
detection of proteins from Western blots. The following
primary antibodies were used: β-actin (Cell Signaling,
1:10,000), Cox-2 (Abcam, 1:1000), β-catenin (Cell
Signaling Technology, 1:1000), phospho-β-catenin
Ser675 (Cell Signaling Technology, 1:1000), and cleaved
caspase 3 (Cell Signaling Technology, 1:1000). Protein
quantification was performed by densitometry (Image
Studio, LI-COR). Protein levels were normalized for
β-actin.

Neurosphere and proliferation assays

ELISA assay

GSCs were diluted to a concentration of 1 cell/100
μL and distributed to a 96-well plate. 3 plates (288 wells)
were used per experiment. Phase microscopy was used to
confirm that each well contained a single cell. Then, 7–10
days later, the number of wells containing spheres was
manually counted and used to calculate the frequency of
self-renewing GSCs. For proliferation studies, cells were
incubated with BrdU and assayed according to protocol
(BrdU Cell Proliferation Kit, Cell Signaling), or assessed
by manual counting.

ELISA assays were performed on conditioned
medium using a PGE2 EIA kit (R&D) according to the
manufacturer’s instructions.
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Quantitative real-time PCR
Total RNA was extracted from cells in culture
using an RNAEasy Kit according to the manufacturer’s
instructions (Qiagen), and cDNA synthesis was
performed using SuperScript II (Invitrogen). Assays were
performed using SYBR Green PCR Master Mix (Applied
82226
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Biosystems) with a StepOne Real Time PCR System.
Predesigned primers were purchased from IDT. Gene
transcript levels were calculated using the ΔΔCt method.

washed with PBS and incubated with Alexa Fluor 488
goat-anti-rabbit (1:400, Invitrogen) secondary antibody
for 1 hr at room temperature. Nuclei were counterstained
with TP-PRO-3 Iodide (ThermoFisher Scientific), washed
and mounted with Vecta Mount mounting medium (Vector
Laboratories, Inc.). Images were acquired with a Quorum
Spinning Disk Confocal Microscope (Olympus) running
Volocity software (Perkin Elmer). Quantification of GFP
signal within RFP-positive cells was performed using
ImageJ (https://imagej.nih.gov/ij/).

Short interfering RNA knockdown
Predesigned short interfering (si)RNAs targeting
human COX-2 and scrambled control siRNAs were
purchased from Qiagen. Two separate siRNAs targeting
different sequences within COX-2 were used to transfect
U87 cells using Lipofectamine 2000 (Invitrogen) versus
scrambled control siRNA. Cells were harvested 48 hours
post-transfection for analysis of protein and RNA levels.

Statistics
All images are representative of results from
three independent experiments unless otherwise stated.
Statistical analyses were performed with Prism 7.0b
(GraphPad), Excel (Microsoft), or R Version 3.1.1
software. The unpaired Student’s t-test was used for
comparisons in experiments with only two groups.
In experiments with more than two comparison
groups, ANOVA was performed. Record of statistical
significance has been included in the figure or figure
legends.

TCGA data analysis
TCGA level 3 data was gathered using TCGAAssembler retrieving RNA-seqV2 data and clinical
data for glioblastoma and low-grade glioma as above.
RSEM normalized expression values were used to group
glioblastomas by COX2 expression. Glioblastomas
expressing COX2 in the first quartile were assigned as
COX2-high expressing and GBMs with COX2 expression
in the 4th quartile was assigned COX2-low expressing.
Boxplots of TCF/LEF target genes were performed
in R using RSEM normalized expression. Statistical
significance was determined with student’s t-test using a
p-value cut-off of 0.05.
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RNA-seq data analysis
RNA-seq fastq data was obtained via accession
no. GSE57872. Paired-end 25 bp reads were mapped
to UCSC human genome (hg38) by STAR (version 2.5
using default parameters). Differential expression of genes
was performed using DESeq2 [58]. Log2 transformed
count matrix for TCF/LEF target genes with adjusted
p-value < 0.05 were plotted in a heatmap with R package
“pheatmap”.
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